Xing, P., Xing, L., Cheng, Y., Luo, Y., Li, Z., Xin, Q., Li, C., Chen, X. G., Wu, Y., Shi, Y. (2025). A phase II study of asandeutertinib (TY-9591) in advanced NSCLC patients with EGFR-positive mutations and brain metastases.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.2004